

**Tissue Regenix Group plc**  
(‘Tissue Regenix’ or the ‘Group’)

**Half-Year Trading Update  
and Notice of Results**

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides an unaudited trading update for the six months ended 30 June 2025.

Total Group revenue for the half year decreased by 6% to 13.8m (H1 2024:14.7m), driven by a decline in orders from the Company's strategic partners due to uncertain economic conditions. The BioRinse portfolio experienced a decline in sales in H1 2025 to 9.8m (H1 2024:10.5m) due to the decline in orders and ongoing delays in obtaining regulatory approval requirements impacting the Group's ability to bring in new customers in new markets. Sales for the dCELL® portfolio, dominated by the division's DermaPure® products, overall decreased by 4% year-on-year (H1 2024:4.2m) due to a decline in orders from its strategic partner. However, revenue increased by 10% year-on-year from its existing direct distribution network, which continues to drive increased commercial activity through the addition of 32 new distributors in H1 2025.

The Group expects to report a positive adjusted EBITDA for H1 2025, and the Board remains confident of achieving profitability at the adjusted EBITDA level for the full year in line with that achieved in FY 2024. Cash position at 30 June 2025 remains sufficient to support the businesses current organic growth plan and drive growth in 2026.

***Jay LeCoque, Executive Chairman of Tissue Regenix, commented** "I'm pleased to join Tissue Regenix as Executive Chairman at this important stage in its development. While today's trading update shows that we have work to do, I am confident in the strength of our people, our technology, and the market opportunities ahead. My immediate priority is to work closely with Daniel and the management team to sharpen our operational and commercial execution, with a clear focus on driving sustainable, long-term earnings growth for our shareholders."*

**Notice of Results**

The Group will publish its interim results on Thursday 18 September 2025.

**Investor Briefing**

Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 16:00 BST on Thursday 18 September. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

<https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor>

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

**For more information:**

**Tissue Regenix Group plc**

Daniel Lee, Chief Executive Officer  
Brandon Largent, Interim Chief Financial Officer

[www.tissueregenix.com](http://www.tissueregenix.com)  
via Walbrook PR

**Cavendish Capital Markets Limited (Nominated Adviser and Broker)**

Geoff Nash/Giles Balleny/Edward Whaley  
Nigel Birks - Life Science Specialist Sales  
Harriet Ward - ECM

Tel: +44 (0) 20 7466 5000

**Walbrook PR (Financial PR and IR)**

Alice Woodings

Tel: +44 (0)20 7933 8780  
[TissueRegenix@walbrookpr.com](mailto:TissueRegenix@walbrookpr.com)

*The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation 'MAR' EU no. 596/2014. Upon the publication of this announcement via the Regulatory Information Service 'RIS', this inside information is now considered to be in the public domain.*

**About Tissue Regenix ([www.tissueregenix.com](http://www.tissueregenix.com))**

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTBIGDCRDGDGUR